IMMIX BIOPHARMA, INC.— Sankey Diagram
Quarterly mode · period ending 2022-12-08 · SEC EDGAR
ComparingFY2022 (Q4) vs FY2021 (Q4)
Revenue
$20M
Gross Profit
$20M
Operating Income
$20M
Net Income
$20M
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2022 (Q4) |
|---|---|
| Revenue | $20M |
| COGS | $0 |
| Gross Profit | $20M |
| R&D | $0 |
| SG&A | $0 |
| D&A | $0 |
| Other OpEx | $0 |
| Operating Income | $20M |
| Interest Exp. | $0 |
| Other Non-Op | $0 |
| Pretax Income | $20M |
| Tax | $0 |
| Net Income | $20M |
QuarterCharts · SEC EDGAR data · IMMX · Comparing FY2022 (Q4) vs FY2021 (Q4)